Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Voyager Therapeutics Inc (NASDAQ: VYGR) closed at $4.16 down -9.37% from its previous closing price of $4.59. In other words, the price has decreased by -$9.37 from its previous closing price. On the day, 0.54 million shares were traded. VYGR stock price reached its highest trading level at $4.49 during the session, while it also had its lowest trading level at $4.15.
Ratios:
For a deeper understanding of Voyager Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.43 and its Current Ratio is at 5.43. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
On December 02, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 03 ’25 when Jorgensen Nathan D. sold 7,666 shares for $4.78 per share. The transaction valued at 36,643 led to the insider holds 123,834 shares of the business.
Fahey Sandell Jacquelyn bought 5,843 shares of VYGR for $27,937 on Oct 03 ’25. On Oct 03 ’25, another insider, Jorgensen Nathan D., who serves as the Officer of the company, bought 7,666 shares for $4.78 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 230750240 and an Enterprise Value of 55361232. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.42 while its Price-to-Book (P/B) ratio in mrq is 0.95. Its current Enterprise Value per Revenue stands at 1.3 whereas that against EBITDA is -0.466.
Stock Price History:
The Beta on a monthly basis for VYGR is 1.23, which has changed by -0.36950547 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, VYGR has reached a high of $7.44, while it has fallen to a 52-week low of $2.64. The 50-Day Moving Average of the stock is -6.66%, while the 200-Day Moving Average is calculated to be 7.80%.
Shares Statistics:
For the past three months, VYGR has traded an average of 754.04K shares per day and 546440 over the past ten days. A total of 55.43M shares are outstanding, with a floating share count of 45.54M. Insiders hold about 17.91% of the company’s shares, while institutions hold 59.82% stake in the company. Shares short for VYGR as of 1760486400 were 3217904 with a Short Ratio of 4.27, compared to 1757894400 on 3140559. Therefore, it implies a Short% of Shares Outstanding of 3217904 and a Short% of Float of 6.92.
Earnings Estimates
Voyager Therapeutics Inc (VYGR) is presently subject to a detailed evaluation by 10.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.34 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.77 and -$2.3 for the fiscal current year, implying an average EPS of -$2.11. EPS for the following year is -$1.41, with 10.0 analysts recommending between -$0.48 and -$2.64.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $7.86M this quarter.It ranges from a high estimate of $12.5M to a low estimate of $5M. As of. The current estimate, Voyager Therapeutics Inc’s year-ago sales were $24.63MFor the next quarter, 12 analysts are estimating revenue of $10.54M. There is a high estimate of $23.4M for the next quarter, whereas the lowest estimate is $5M.
A total of 12 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $45.13M, while the lowest revenue estimate was $21.67M, resulting in an average revenue estimate of $30.08M. In the same quarter a year ago, actual revenue was $80MBased on 12 analysts’ estimates, the company’s revenue will be $62.29M in the next fiscal year. The high estimate is $145.95M and the low estimate is $8M.
